#oral-anti-obesity-medications

#oral-anti-obesity-medications

A new ZipHealth survey of over 1,000 workers found that nearly half (47%) of Gen Z said GLP-1 coverage would affect their choices between two similar jobs.

We've created a small molecule chemical which gets in your body very well. It can mimic the effects of the peptide and can be taken more conveniently any time of day without any food or water restrictions.

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.

"People tend to immediately think of neurons when they think about how the brain works. But we're finding that astrocytes, what we used to think of as just secondary support cells, are also participating in how our brains regulate how much we eat."

The findings show that when body fat is measured using dual-energy X-ray absorptiometry (DXA), considered the gold standard method, BMI often incorrectly labels individuals as overweight or obese.

Emma Dyer remembers the moment she clicked "buy now" on a set of weightloss jabs she found online. She had no medical consultation, no ID checks, and no questions about her history of anorexia and bulimia. "It was just so easy - too easy," she says. "They never asked for my medical history or what medication I was taking. It was like buying groceries."

In the mid-1990s, child mental health researchers at top New York institutions injected grade-school boys with fenfluramine, also known as the diet drug "fen-fen," a substance that was later banned by the Food and Drug Administration, due to its links to valvular heart disease and pulmonary hypertension. The boys were all Black or Hispanic by design: Eligible participants were required to be African American or Hispanic because they were deemed to be at higher risk for developing disruptive behaviors.

A Colorado endocrinologist helped spark a quiet revolution in weight care by changing how primary care clinics talk about - and treat - obesity. Instead of vague advice to "eat less and exercise more," a new system called PATHWEIGH gave patients a clear, judgment-free path to real medical support for weight management.

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday - two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications. Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month.